Glaukos Corporation (NYSE:GKOS – Get Free Report) Director Leana Wen sold 525 shares of Glaukos stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $167.63, for a total value of $88,005.75. Following the transaction, the director directly owned 21,092 shares in the company, valued at approximately $3,535,651.96. The trade was a 2.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Glaukos Price Performance
Shares of NYSE:GKOS opened at $170.60 on Thursday. The firm’s 50 day simple moving average is $141.42 and its two-hundred day simple moving average is $126.46. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. The company has a market capitalization of $10.06 billion, a P/E ratio of -52.49 and a beta of 0.78. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $184.00.
Glaukos (NYSE:GKOS – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.Glaukos’s revenue for the quarter was up 49.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.24) EPS. Research analysts expect that Glaukos Corporation will post -0.35 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on Glaukos
Institutional Trading of Glaukos
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its holdings in Glaukos by 77.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock valued at $575,844,000 after acquiring an additional 2,329,608 shares during the period. Wellington Management Group LLP boosted its stake in shares of Glaukos by 10.4% during the third quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after purchasing an additional 336,266 shares during the period. Primecap Management Co. CA grew its holdings in shares of Glaukos by 49.8% in the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after purchasing an additional 1,123,140 shares during the last quarter. State Street Corp grew its holdings in shares of Glaukos by 0.9% in the fourth quarter. State Street Corp now owns 2,122,402 shares of the medical instruments supplier’s stock worth $239,640,000 after purchasing an additional 18,040 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its stake in Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after buying an additional 68,497 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.
About Glaukos
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
- Five stocks we like better than Glaukos
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
